CHARLOTTESVILLE, Virginia, June 23 /PRNewswire/ -- Biovista Inc. today announced that BVA-601, its small-molecule drug targeting epilepsy, has shown positive results in the Kainic acid murine model of temporal lobe epilepsy. BVA-601, an existing drug that Biovista repositioned in epilepsy, exhibits both anti-epileptic and neuroprotective activity. In this pre-clinical trial, BVA-601 induced a statistically significant decrease of epileptic activity in mice pre-treated with Kainic acid.
"We are pleased with these initial results that confirm the predicted efficacy of BVA-601 and encourage us to further test and develop this compound in a disease area where there is a need for new, patient-friendly therapies," said Aris Persidis, Ph.D., President of Biovista. "This successful repositioning builds on our previously reported success with BVA-101 in multiple sclerosis, expanding our CNS portfolio. At the present time we are exploring all options available to us, including the further co-development with a pharmaceutical company and the licensing of the IP to a generics company," added Dr. Persidis.
For a non-confidential information pack on BVA-601, contact Biovista at email@example.com.
About Biovista's BVA-601 trial in the Kainic acid model of epilepsy
Epilepsy is a common chronic neurological disorder characterized by
recurrent unprovoked seizures. These seizures may be transient signs and/or
symptoms due to abnormal, excessive or synchronous neuronal activity in the
brain. Epilepsy is one of the world's oldest recognized conditions, affecting
around 50 million people worldwide. Fear, discrimination and social stigma
have surrounded epilepsy for centuries. Some of the stigma continues today in
many countries impacting the quality of life of people with the
|SOURCE Biovista Inc.|
Copyright©2009 PR Newswire.
All rights reserved